Introducing a New Session on Industry Innovations in MSK Health

At the 2025 Annual Meeting, ORS will be hosting a lunch-and-learn educational session intended to highlight specific technical advancements that have been introduced to the market within the past two years from the orthopaedic industry. It is essential to understand that accepted abstracts will not be marketing pitches! Rather, the goal of this session is to showcase the science and technology behind the advancement.

Congratulations to the 2025 Winners

Brian Godshaw
Quadriceps Tendon Anterior Cruciate Ligament Reconstruction Augmentation with PLLA-Reinforced Bioinductive Scaffold

Ochsner Andrews Sports Medicine Institute
New Orleans, LA

Undergraduate: Clemson University
Medical School: Medical College of Wisconsin
Residency: Ochsner Clinic Foundation
Fellowship: University of Pittsburgh Medical Center (Sports Medicine)
Professional Experience: Assistant Program Director – Orthopedic Residency (Ochsner Clinic Foundation); Surgical Subspecialty Clerkship Director – University of Queensland, Ochsner Clinical School; Director of Orthopedic Research – Ochsner Clinic Foundation; Associate Team Physician/Orthopedic Surgeon – New Orleans Pelicans

Anthony N Khoury
Double-Row Speed Bridge Rip-Stop Repair: A Novel Technique to Improve Insertional Achilles Tendon Repair

Anthony N. Khoury, PhD is a Sr. Scientific Specialist at Arthrex, Inc. Prior to joining Arthrex in 2020, Anthony completed his graduate studies in Biomedical Engineering at the University of Texas at Arlington.

Francisco Silva
Next Generation Orthobiologic Therapy for Chronic Lumbar Disc Disease: Initial Phase 2 Data of Hypoxic Cultured Mesenchymal Stem Cells

Francisco Silva is Vice President of Research and Development at BioRestorative Therapies, where he leads a team of scientists developing cell-based therapeutics targeting musculoskeletal and metabolic disorders. Currently Mr. Silva is the principal investigator of an FDA Phase 2 clinical trial using hypoxic cultured mesenchymal stem cells for chronic lumbar disc disease.

Mr. Silva has extensive experience in developing and translating cell-based therapeutics, he was one of the first to publish the use of stem cells in patients suffering from spinal cord injury in 2008. Mr. Silva is also developing cell-based approaches to treat metabolic disorders and was one of the first to develop an artificial 3D brown adipose transplant using human brown adipose stem cells. In addition, he has pioneered the global commercialization of cell based therapeutics and is a co-founder of Cellular Performance Institute, a global leader in regenerative medicine. His research has led to the discovery of novel cell types isolated from umbilical cord, bone marrow and adipose tissue, he has several peer reviewed papers focused on regenerative medicine, and numerous issued patents in the field.

Faisal Mirza
Advanced Knee Wearable Athletic Sleeve uses Machine Learning to Predict the Risk of ACL Injury with 98% Accuracy

Dr. Faisal Mirza is a Knee & Shoulder Surgeon, Entrepreneur and Co-Founder COO of Kinisi Inc, a deep tech healthcare technology company whose goal is to transform human health by improving and maintaining joint stability. In his part-time, Dr. Mirza manages sports injuries at Zuckerberg SF General Hospital as UCSF Clinical Associate Professor and work-related injuries at Concentra. He was raised in Canada where he completed his education at University of Western Ontario and McMaster University. Following his training, he joined Stanford University as Clinical Assistant Professor of Orthopaedics at the VA Palo Alto, after which a Device Outcomes Grant led him to the FDA as Principal Investigator and Medical Officer. From the FDA, Dr. Mirza was recruited into biotechnology by Amgen as Global Bone Health Development Medical Director based on his passion for bone and joint health. Dr. Mirza is published in peer-reviewed journals and has lectured internationally on innovation and technology in shoulder, sports medicine, device outcomes, bone and joint health, additive manufacturing, and regulatory pathways. He has a passion for art, having given art workshops to disabled veterans and been exhibited nationally. Faisal spends his free time with his two amazing kids telling Dad jokes while hiking, cycling, swimming, playing tennis and chess.

Benjamin Smith
The SutureLoc™ Implant: An Adjustable Knotless All-Suture Anchor for Transtibial Aperture Fixation of Meniscal Roots

Ben Smith is a Senior Research Engineer at Arthrex. Ben collaborates with orthopedic surgeons to conduct biomechanical research studies evaluating next-generation surgical treatments, primarily for knee and hip procedures. His research aims to provide timely scientific evidence that products and techniques are truly safe and effective.

Chris Steffi
Bioprinting of 3D Highly Mineralized Patient-Specific Bone Disease Models

Dr. Chris Steffi is a Postdoctoral Research Fellow at ETH Zurich and one of the co-founders of CompagOs, an ETH Zurich Spin-off. During her PhD and postdoctoral work at the National University of Singapore, she developed in vitro models to study drug delivery and biomaterial functionalization for bone tissue engineering. Currently, Dr. Steffi focuses on in vitro bone models for fracture phenotypes and osteosarcoma for personalized medicine, expansion, and biobanking of rare disease samples. She is a recipient of the NUSMed Postdoctoral Fellowship, NUS Research Fellowship, and the Council of Scientific & Industrial Research “Catch Them Young” scholarship.

Call for Session Speakers Now Closed

We invite submissions from all industry participants for this session. Talks will be selected from the submissions with the intent to have a diverse set of technologies and industry representatives. Details on the submission process are below. It is expected that each accepted abstract will be allocated 8-12 minutes during the lunch session for presentation.

Submission Details

  • Limited to 400 words, all inclusive, and may include one image of the product/technology.
  • Must reference the product introduced to the market, the year of introduction, and the specific technical advancement(s) within the product to be highlighted.
  • The lead and presenting author is expected to be primarily affiliated with an industry entity.

The Submission Deadline was Monday, September 16, 2024.

For more information, please contact [email protected].